Clinical trialsOfficial
Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48
🇬🇧 MHRA · Thu 12 Nov 2026
MHRA issued a Class 4 (advisory) defect notification after Star Pharmaceuticals reported a typographical error on the front face of the carton for Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets, where the hydrochlorothiazide strength is printed as "12. mg" instead of "12.5 mg". The risk is low, but the incorrect strength on the outer packaging could cause confusion and may require a correction of the labelling.
Summary written by VigiEye from the official notice. AI-assisted; check the source before acting.
More Clinical trials
All →
Clinical trialsCompany releaseCalidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
🇺🇸 Calidi Biotherapeutics, Inc. (CLDI) · Fri 13 Nov 2026
Clinical trialsCompany releaseIRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
🇺🇸 IRulya Therapeutics Inc. (IRLA) · Fri 13 Nov 2026
Clinical trialsCompany releaseMacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
🇺🇸 Macrogenics Inc (MGNX) · Fri 13 Nov 2026
Clinical trialsCompany releaseCerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
🇺🇸 Cerenome, Inc. (CNSY) · Fri 13 Nov 2026
Clinical trialsCompany releaseCuris reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
🇺🇸 Curis Inc (CRIS) · Fri 13 Nov 2026
Clinical trialsCompany releaseBluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027
🇺🇸 Bluejay Diagnostics, Inc. (BJDX) · Fri 13 Nov 2026